Acerola fruit by-product alleviates lipid, glucose, and inflammatory changes in the enterohepatic axis of rats fed a high-fat diet. (1st March 2023)

• Record Type: Journal Article
• Authors: Batista, Kamila Sabino; Soares, Naís Lira; Dorand, Victor Augusto Mathias; Alves, Adriano Francisco; dos Santos Lima, Marcos; de Alencar Pereira, Ramon; Leite de Souza, Evandro; Magnani, Marciane; Persuhn, Darlene Camati; de Souza Aquino, Jailane
• Is Part Of: Food chemistry. Volume 403(2023)
• Publication Date: 2023-03-01
• Subjects: Fruit by-product -- Glucose -- Lipids -- Macrophages -- Malpighia emarginata -- Organic acids; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; 664
• DOI: 10.1016/j.foodchem.2022.134322
• Languages: English
• ISSNs: 0308-8146

Abstract

Graphical abstract: Highlights: Acerola by-product (ABP) reduced serum lipid values and liver fat accumulation. ABP regulated organic acid synthesis, faecal and colonic microbial growth. ABP reduced M1 macrophage and increased M2 macrophage in the colon and liver. ABP increased insulin tolerance in rats fed high-fat diet. Abstract: Acerola ( Malpighia emarginata ) by-product (ABP) has various bioactive compounds with hypoglycaemic, antioxidant and anti-inflammatory activity. The ABP effects on the biochemical changes in the enterohepatic axis caused by a high-fat diet (HFD) remains unclear. This study assessed whether the ABP or fenofibrate administration for 28 days interferes in lipid, glucose, or inflammatory changes in the enterohepatic axis of rats fed HFD. ABP induced in the rats fed HFD a reduction in body weight, serum lipids, blood glucose, and liver fat accumulation; increased insulin tolerance, and faecal bile acid excretion; regulated organic acid synthesis, faecal and colonic microbial growth; reduced M1 macrophage and increased M2 macrophage infiltration in the colon and liver, respectively. The fenofibrate did not improve the lipid or glucose alterations in enterohepatic axis of rats fed HFD. ABP has functional/nutraceutical potential in treating HFD-induced metabolic disorders with beneficial effects on lipid and glucose metabolism, and reduction of inflammation.